CD666
CD666 is a selective retinoic acid receptor-γ (RAR-γ) agonist with a Kd of 68 nM. CD666 inhibits proliferation of cancer cells and shows synergistical effects and anti-AP-1 activity with IFN-γ. CD666 can be used for the research of breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 144006-45-1
- Formule: C24H28O3
- Masse moléculaire:364.48
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform AP-1
More
Activité biologique
Description
IC50 & Target
[1]|
RAR-γ 68 nM (Kd) |
In Vitro
CD666 binds selectively to recombinant RAR-γ with a Kd of 68 nM, showing ~33-fold and ~34-fold lower affinity for RAR-α (Kd = 2240 nM) and RAR-β (Kd = 2300 nM), respectively[1].
CD666 (0.1-1000 μM) potently inhibits proliferation of RA-sensitive MCF-7, ZR-75-1, T47D, and SKBR-3 human breast cancer cell lines, but does not inhibit proliferation of Retinoic acid (HY-14649 )-resistant 734-B and BT-20 cell lines when used alone[1].
CD666 acts synergistically with IFN-γ to inhibit proliferation of MCF-7, SKBR-3, BT-20, ZR-75-1, T47D, and 734-B human breast cancer cell lines, with combination
index values < 1 across all tested inhibitory concentrations[1].
CD666 (1 μM; 24 h) alone does not suppress TPA-mediated AP-1 activity in MCF-7 human breast cancer cells, but in combination with IFN-γ, it significantly reduces AP-1 promoter activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 144006-45-1
-
Masse moléculaire 364.48
-
Formule C24H28O3
-
SMILES
CC1(C2=CC(C(O)/C=C/C3=CC=C(C=C3)C(O)=O)=CC=C2C(C)(CC1)C)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CD666 Related Classifications
HY-183139 Related Classifications
Powered by Bioz